Bandini Marco, Marchioni Michele, Pompe Raisa S, Tian Zhe, Martel Tristan, Chun Felix K, Cindolo Luca, Kapoor Anil, Montorsi Francesco, Shariat Shahrokh F, Briganti Alberto, Karakiewicz Pierre I
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada.
Can Urol Assoc J. 2018 Jul;12(7):E325-E330. doi: 10.5489/cuaj.4854. Epub 2018 Mar 19.
Contemporary data regarding the effect of age, especially in elderly patients, on cancer-specific mortality (CSM) for pT1a renal cell carcinoma (RCC) are lacking. The objective of the current study is to evaluate CSM in a large population-based cohort of surgically treated pT1a RCC patients according to age groups.
Within the Surveillance Epidemiology and End Results database (2000-2013), we identified 37 121 pT1a RCC patients who underwent either partial or radical nephrectomy. The population was stratified into five groups according to decades: <50, 50-59, 60-69, 70-79, and ≥80 years. The effect of age on CSM was evaluated using competing risks regression models according to Fuhrman grade (FG). Analyses were repeated in clear-cell RCC (ccRCC).
Patients aged 50-59 (9615), 60-69 (10 762), 70-79 (7096), and ≥80 (1789) years demonstrated higher rate of CSM compared to patients aged <50 (7856) years (hazard ratios [HR] 2.11, 3.04, 4.47, and 7.56, respectively; all p<0.001). The effect of age on CSM in FG 1-2 patients resulted in HRs ranging from 2.01-8.23 for the same age decades (all p< 0.001). Similarly, the effect of age on CSM in FG 3-4 patients resulted in HRs ranging from 2.38-5.92, respectively (all p<0.001). Virtually the same results were recorded in ccRCC patients.
Older age is associated with higher CSM in surgically treated patients with pT1a RCC. This effect seems to be more pronounced in patient with FG 1-2 disease. This observation should be considered when making treatment decisions in elderly patients.
目前缺乏关于年龄,尤其是老年患者年龄,对pT1a期肾细胞癌(RCC)患者癌症特异性死亡率(CSM)影响的当代数据。本研究的目的是根据年龄组评估接受手术治疗的pT1a期RCC患者的大型人群队列中的CSM。
在监测、流行病学和最终结果数据库(2000 - 2013年)中,我们确定了37121例接受部分或根治性肾切除术的pT1a期RCC患者。根据年代将人群分为五组:<50岁、50 - 59岁、60 - 69岁、70 - 79岁和≥80岁。根据Fuhrman分级(FG),使用竞争风险回归模型评估年龄对CSM的影响。在透明细胞肾细胞癌(ccRCC)患者中重复进行分析。
与<50岁(7856例)的患者相比,50 - 59岁(9615例)、60 - 69岁(10762例)、70 - 79岁(7096例)和≥80岁(1789例)的患者表现出更高的CSM发生率(风险比[HR]分别为2.11、3.04、4.47和7.56;所有p<0.001)。在FG 1 - 2级患者中,年龄对CSM的影响导致相同年龄年代的HR范围为2.01 - 8.23(所有p<0.001)。同样,在FG 3 - 4级患者中,年龄对CSM的影响导致HR分别为2.38 - 5.92(所有p<0.001)。在ccRCC患者中记录到几乎相同的结果。
在接受手术治疗的pT1a期RCC患者中,年龄较大与较高的CSM相关。这种影响在FG 1 - 2级疾病患者中似乎更为明显。在为老年患者做出治疗决策时应考虑这一观察结果。